06.27.2025
Science
Software-Enhanced Drugs
Breast Cancer
Where science meetssoftware.
Software as treatment.
Delivered to your phone.
Prescribed by your physician.
Click Therapeutics is redefining modern medicine with patient-centric digital treatments. Operating at the intersection of biology and technology, Click combines neuroscience with the power of software, creating a new way to treat disease.
Digital treatments, tangible outcomes.
We develop, validate, and commercialize software as prescription medical treatments for people with unmet medical needs.
Click SE
Medicine just got a digital upgrade: Software-Enhanced Drugs™
Click SE™ solutions combine software with pharmacotherapy to create software-enhanced drug™ treatments, designed to deliver added clinical benefit to patients compared to drug alone.
One powerful platform. Many ways to treat disease.
Our multimodal, platform-based approach targets disease and drives outcomes from multiple different angles, combining scientifically proven therapies with proprietary neuromodulatory mechanisms of action to deliver clinically-meaningful interventions.
Latest at Click
Recent publications
Collaborators
By embracing collaborations that build on our unique areas of expertise, we’re powering a new era of medicine.
Collaborating on:
CT-152
Collaborating on:
CT-155
Collaborating on:
CT-156
Contact
Join us in our journey to raise the bar of modern medicine with software as treatments.
Join usStay up to date with news and updates
Click Therapeutics Today
In numbers
Upcoming event
Jul24Patients, Pipeline, and Promise: Software-Enhanced Drugs
Live webinar Thursday 7/24 at 1 PM ET
Speaker:
David Benshoof Klein
Founder & CEO
Fierce Pharma Virtual Webinar
Products Pipeline
Boehringer and Click Therapeutics present pivotal data for investigational prescription digital therapeutic CT-155 showing a statistically significant reduction in negative symptoms of schizophrenia
Boehringer Ingelheim and Click Therapeutics today shared data from the pivotal Phase III CONVOKE study (NCT05838625) of CT-155 (BI 3972080), an investigational prescription digital therapeutic (PDT) used as an adjunct to standard of care antipsychotic therapy for experiential negative symptoms of schizophrenia. The data were presented during an oral session at the 38th Annual European College of Neuropsychopharmacology (ECNP) Congress in Amsterdam and full results will be published at a later date.
The study met its primary endpoint, which was change in experiential negative symptoms from baseline to 16 weeks as measured by the Clinical Assessment Interview for Negative Symptoms, Motivation and Pleasure Scale (CAINS-MAP). Treatment with CT-155 demonstrated a Cohen's D effect size of -0.36 (p value= 0.0003) reflective of a 6.8-point improvement of negative symptoms severity as measured by CAINS-MAP at 16 weeks (vs. 4.2-point in digital control arm), representing a 62% relative improvement.
In numbers
Upcoming event
Jul24Patients, Pipeline, and Promise: Software-Enhanced Drugs
Live webinar Thursday 7/24 at 1 PM ET
Speaker:
David Benshoof Klein
Founder & CEO
Fierce Pharma Virtual Webinar
Products Pipeline
Boehringer and Click Therapeutics present pivotal data for investigational prescription digital therapeutic CT-155 showing a statistically significant reduction in negative symptoms of schizophrenia
Boehringer Ingelheim and Click Therapeutics today shared data from the pivotal Phase III CONVOKE study (NCT05838625) of CT-155 (BI 3972080), an investigational prescription digital therapeutic (PDT) used as an adjunct to standard of care antipsychotic therapy for experiential negative symptoms of schizophrenia. The data were presented during an oral session at the 38th Annual European College of Neuropsychopharmacology (ECNP) Congress in Amsterdam and full results will be published at a later date.
The study met its primary endpoint, which was change in experiential negative symptoms from baseline to 16 weeks as measured by the Clinical Assessment Interview for Negative Symptoms, Motivation and Pleasure Scale (CAINS-MAP). Treatment with CT-155 demonstrated a Cohen's D effect size of -0.36 (p value= 0.0003) reflective of a 6.8-point improvement of negative symptoms severity as measured by CAINS-MAP at 16 weeks (vs. 4.2-point in digital control arm), representing a 62% relative improvement.